A Journey of Innovation
MOTYS Development
MOTYS was developed and characterized by scientists at Bioventus. Based on their efforts a global clinical program was launched and several studies were completed, including a Phase 2 dose-finding trial.
Doron Therapeutics Founded
Doron is founded as a management-led spinout from Bioventus, a market leader in OA. Doron Therapeutics licensed worldwide rights to MOTYS to continue its development. Excited by the huge potential of this placental-derived biologic, our team is committed to bringing innovation to those suffering from musculoskeletal pain.
Series A Financing Secured
Closed $11M in series A funding led by SPRIM Global Investments to support the clinical advancement of MOTYS™.
View Press Release →Fast Track & RMAT Designation Granted by FDA
Received Fast Track & Regenerative Medicine Advanced Therapy (RMAT) designation, recognizing its potential to address serious unmet need in osteoarthritis and validating the robust clinical evidence to date.
View Press Release →Positive End-of-Phase 2 and Initial RMAT Meeting With FDA
Doron Therapeutics has completed a successful End-of-Phase 2 and initial RMAT meeting with the FDA, confirming the Phase 3 clinical program's design and scope for MOTYS in treating knee osteoarthritis.
View Press Release →First Patient Dosed in First Phase 3 Trial
With over 300 patients studied, MOTYS™ has entered Phase 3 development. Our singular focus ensures that this breakthrough therapy reaches patients who can benefit from its disease-modifying potential.
View Press Release →Additional Capital Raised
Since its inception, Doron has raised a total of $35M to date. We have been highly capital efficient in forming a Newco, restarting operations and clinical manufacturing, completing multiple FDA meetings, and driving enrollment in our pivotal Phase 3 study.
